111 / 1498
Nivolumab in clinical trials
All B-Cell Lymphoma Patient Responses
Percent Change from Baseline
0
8
16
24
32
40
48
56
64
72
80
88
96
Time since first dose (weeks)
Diffuse Large B-Cell lymphoma
Follicular B-Cell Lymphoma
Other B-Cell Lymphoma
Upper Limit Approximately 540%
Upper Limit Approximately 238%
* **
* **
*
Upper Limit Approximately 615%
Moskowitz C, ASH 2014
-30
-20
-10
0
10
20
30
40
50
60
70
80
90
100
110
120
-40
-50
-60
-70
-80
-90
-100